Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CMA identifies 'significant' concerns over infant formula market

(Sharecast News) - The Competition and Markets Authority said on Friday that it will press ahead with its study of the infant formula and follow-on market after finding earlier this year that prices remained at historically high levels. The regulator, which launched an investigation in February, said it had decided not to carry out a full-scale investigation "at this stage".

The CMA took action at the time because it was concerned that suppliers may face insufficient incentives to offer infant formula at competitive prices, and that parents and carers may not always have the information they need to make well-informed choices.

For public health reasons, the advertising of infant formula is restricted, and other promotional and commercial activities are also restricted to avoid inducing the purchase of infant formula, the CMA noted.

It said on Friday that since price reductions cannot be promoted, this has the effect of "softening competition" on price.

"The CMA has identified significant concerns that the combined effect of the current regulatory framework, the behaviour of manufacturers and suppliers and the needs and reactions of people buying formula, are resulting in poor market outcomes," it said in a statement.

"The CMA considers these concerns will be best addressed by progressing with our market study and developing recommendations to governments to improve these market outcomes rather than moving to a more extensive market investigation."

The regulator expects to publish an interim report setting out its concerns along with provisional recommendations for action in October this year.

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.